Why Getinge (OM:GETI B) Is Getting Attention Again
Why Getinge’s latest earnings grabbed attention
Getinge (OM:GETI B) has attracted fresh attention after its third quarter update, where net income and earnings per share moved higher year on year while sales stayed close to prior levels.
Recent months have been kinder to Getinge shareholders, with a 12.7% 1 month share price return and a 27.6% share price gain year to date. The 1 year total shareholder return of 27.4% hints that momentum has picked up again after a weaker 5 year total shareholder return, which shows a 21.1% decline.
The third quarter earnings update on 21 October 2026, followed by news that the President of Acute Care Therapies plans to depart, has kept Getinge in focus as investors reassess both profitability trends and leadership continuity at a share price of SEK 277.7.
Compare Getinge’s earnings momentum with a curated group of hospital and medtech players by scanning 125 healthcare AI stocks for your next watchlist candidates.
Getinge now trades slightly above the average analyst price target while still screening at a sizeable intrinsic value discount. Is the market rightly cautious after the recent earnings jump and leadership change, or too restrained?
Most Popular Narrative: 2% Overvalued
Getinge’s most followed narrative currently places fair value at SEK 271.36, slightly below the last close of SEK 277.7. This frames the stock as modestly ahead of that fair value line while still backed by improving profitability and recurring revenue.
The current valuation suggests that Getinge is fairly valued and already reflects a mix of continued margin progress, growth in franchises such as Sterile Transfer and Acute Care Therapies, and manageable pressure from China and tariffs.
See why 8 investors see Getinge as 2% overvalued.
Result: Fair Value of SEK271.36 (OVERVALUED)
Still, tariff costs and inflation in labor and logistics, combined with a tougher backdrop in China, could quickly challenge the current Getinge fair value story.
Find out about the key risks to this Getinge narrative.
Another view on Getinge’s valuation
The popular narrative paints Getinge as only about 2% overvalued against a SEK 271.36 fair value, which leans on earnings forecasts and analyst targets. A different lens tells a sharper story. At a P/E of 26.7x, the stock trades below the European medical equipment group on 28.4x and under an estimated fair ratio of 29.3x. In other words, the market is assigning a discount where peers and the fair ratio point to richer pricing. Is that a margin of safety or a signal that expectations might already be stretched if earnings waver?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed signals around Getinge leave you unsure, treat that as your cue to move fast, examine the data carefully, and form your own stance. To weigh the upside against the pressure points in one place, start with the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Getinge?
Momentum in Getinge might have your attention, but your portfolio deserves a deeper bench of opportunities that line up with your own risk and return style.
- Target value potential by scanning for companies that combine quality fundamentals with discounted pricing through the 197 high quality undervalued stocks.
- Strengthen portfolio resilience by focusing on businesses with conservative leverage and robust financial footing using the 218 resilient stocks with low risk scores.
- Hunt for future leaders by zeroing in on under-followed stocks with strong fundamentals through the 612 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com